NCT05022030View on ClinicalTrials.gov

First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes

PHASE2RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

July 21, 2021

Primary Completion Date

June 1, 2025

Study Completion Date

June 1, 2026

Conditions
Colo-rectal CancerCapecitabineCetuximab
Interventions
DRUG

mCapOX plus cetuximab

capecitabine 1000mg/m2 po bid d1-7+oxaliplatin ivgtt 85mg/m2 d1+cetuximab ivgtt 500mg/m2, q2w

DRUG

mFOLFOX6 plus cetuximab

oxaliplatin ivgtt 85mg/m2 d1+ leucovorin ivgtt 400mg/m2 d1+ fluorouracil iv bolus 400mg/m2 d1+ fluorouracil 2400mg/m2 continuous infusion for 46h+cetuximab ivgtt 500mg/m2, q2w

Trial Locations (1)

610041

RECRUITING

West China Hospital of Sichuan University, Chengdu

All Listed Sponsors
collaborator

First Affiliated Hospital of Chongqing Medical University

OTHER

lead

West China Hospital

OTHER